Benjamin Cameron, DO
Internal Medicine · Longview, TXNPI 1205248424
Payments from drug & device makers
Across 182 payments — averaging $17.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$568
- Lilly USA, LLC$383
- Pfizer$274
- GSK$242
- AstraZeneca$237
- Biohaven Pharmaceutical Holding Company Ltd.$145
- plus $1K from 25 others
What the payments were for
- Food & beverage$3,08399%
- Education$201%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 30 | $568 |
| Lilly USA, LLC | 31 | $383 |
| Pfizer | 17 | $274 |
| GSK | 14 | $242 |
| AstraZeneca | 13 | $237 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $145 |
| Boehringer Ingelheim | 8 | $140 |
| Amgen | 8 | $138 |
| AbbVie | 7 | $126 |
| Bayer | 7 | $115 |
| Idorsia Pharmaceuticals US Inc | 5 | $107 |
| Axsome Therapeutics, Inc. | 5 | $95 |
| Kowa Pharmaceuticals America, Inc. | 5 | $92 |
| Boston Scientific | 3 | $61 |
| Merck | 3 | $38 |
| Xeris Pharmaceuticals, Inc. | 2 | $34 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $29 |
| Currax Pharmaceuticals LLC | 2 | $29 |
| GE HealthCare | 2 | $28 |
| Corium, LLC | 4 | $27 |
| Phathom Pharmaceuticals, Inc. | 2 | $25 |
| Cequr Corporation | 1 | $22 |
| Abiomed | 1 | $21 |
| Abbott | 1 | $21 |
| Halozyme Inc | 1 | $20 |
| Astellas Pharma US Inc | 1 | $16 |
| Linus Health, Inc. | 1 | $15 |
| Amarin Pharma, Inc. | 1 | $15 |
| Exact Sciences | 1 | $14 |
| Corcept Therapeutics | 1 | $14 |
| Johnson & Johnson | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$117
How this compares
$3,104 in reported general payments places this provider in the 80th percentile of 7,675 internal medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 92 | $102,002 |
| EliquisApixaban | 60 | $72,503 |
| OzempicSemaglutide | 29 | $45,720 |
| MounjaroTirzepatide | 31 | $45,474 |
| TrulicityDulaglutide | 25 | $27,448 |
| XareltoRivaroxaban | 24 | $25,697 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 30 | $23,684 |
| FarxigaDapagliflozin Propanediol | 13 | $18,997 |
| Repatha SureclickEvolocumab | 20 | $18,415 |
| Rosuvastatin Calcium | 502 | $6,607 |
| Breo ElliptaFluticasone/Vilanterol | 16 | $6,377 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 13 | $6,289 |
| JanuviaSitagliptin Phosphate | 11 | $6,056 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 48 | $5,376 |
| Pantoprazole Sodium | 374 | $4,982 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $140 | $102,00292 claims |
| Lilly USA, LLCMounjaro, Trulicity | $383 | $72,92256 claims |
| PfizerEliquis | $274 | $72,50360 claims |
| Novo NordiskOzempic | $568 | $45,72029 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $242 | $30,06146 claims |
| Johnson & JohnsonXarelto | $14 | $25,69724 claims |
| AstraZenecaFarxiga | $237 | $18,99713 claims |
| MerckJanuvia | $38 | $6,05611 claims |
| AbbVieSynthroid | $126 | $2,88730 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 7,675 internal medicine providers in Texas.
Other internal medicine in Longview
- Kathleen HarrisLongview$3.1M
- Jan BurgerHouston$47.3M
- Nitin JainHouston$33.2M
- Muhammad IrfanTomball$30.6M
- Aung NaingHouston$30.6M
- Robert BassSan Antonio$25.6M
- Preetesh JainHouston$19.5M
- Paolo StratiHouston$19.2M
- Hernan SalazarSan Antonio$18.5M
- Nicholas ShortHouston$17.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.